Cullinan Oncology LLC (CGEM NASDAQ) stock market data APIs
$15.0812
-0.33(-2.2%)
as of May 6, 2026
Try our APIs with
free plan!
Cullinan Oncology LLC Financial Data Overview
Price chart is built with
Anychart
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Prev. Close
15.0812
Open
14.7526
High
15.4361
Low
14.6264
52 wk Range
5.68-16.74
Market Cap
918 M
Shares Outstanding
61 451 K
EPS
-0.77
Beta
-0.089
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cullinan Oncology LLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cullinan Oncology LLC data using free add-ons & libraries
Get Cullinan Oncology LLC Fundamental Data
Cullinan Oncology LLC Fundamental data includes:
- Net Revenue:
- EBITDA: -241 336 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-05
- EPS/Forecast: -0.8739
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cullinan Oncology LLC News
New
Will Health Benefits Weakness Drag Elevance's Q1 Earnings?
Elevance Health, Inc. ELV is set to report its first-quarter 2026 results on April 22, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is curren...
Commit To Purchase Cullinan Therapeutics At $9, Earn 25.1% Annualized Using Options
Investors considering a purchase of Cullinan Therapeutics Inc (Symbol: CGEM) shares, but cautious about paying the going market price of $13.20/share, might benefit from considering selling puts among...
Cullinan Reports Wider Loss In Q4, Updates Milestones
(RTTNews) - Cullinan Therapeutics, Inc. (CGEM), a clinical-stage biopharmaceutical company, Wednesday announced wider net loss for the fourth quarter, compared to the previous year. Quarterly net los...
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, SL...
Get Cullinan Oncology LLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
